Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free BCAX Stock Alerts

Bicara Therapeutics (BCAX) Financials

Bicara Therapeutics logo
$23.78 +0.62 (+2.68%)
Closing price 05/6/2026 04:00 PM Eastern
Extended Trading
$23.51 -0.27 (-1.15%)
As of 08:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Bicara Therapeutics

Annual Income Statements for Bicara Therapeutics

This table shows Bicara Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -52 -68 -138
Consolidated Net Income / (Loss)		 -52 -68 -138
Net Income / (Loss) Continuing Operations		 -52 -68 -138
Total Pre-Tax Income 		-52 -68 -138
Total Operating Income		 -40 -82 -156
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 40 82 156
Selling, General & Admin Expense		 9.27 19 31
Research & Development Expense		 31 64 125
Total Other Income / (Expense), net		 -12 15 18
Interest & Investment Income		 1.31 15 18
Income Tax Expense		 0.01 0.19 0.22
Basic Earnings per Share		 ($89.61) ($4.05) ($2.52)
Weighted Average Basic Shares Outstanding		 580.11K 16.81M 54.68M
Diluted Earnings per Share		 ($89.61) ($4.05) ($2.52)
Weighted Average Diluted Shares Outstanding		 580.11K 16.81M 54.68M
Weighted Average Basic & Diluted Shares Outstanding		 - 54.52M 65.47M

Quarterly Income Statements for Bicara Therapeutics

This table shows Bicara Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -23 -13 -17 -17 -21 -37 -27 -36 -37
Consolidated Net Income / (Loss)		 -23 -13 -17 -17 -21 -37 -27 -36 -37
Net Income / (Loss) Continuing Operations		 -23 -13 -17 -17 -21 -37 -27 -36 -37
Total Pre-Tax Income 		-23 -13 -17 -17 -21 -37 -27 -36 -37
Total Operating Income		 -9.53 -15 -20 -21 -27 -42 -32 -41 -41
Total Operating Expenses		 9.49 15 20 21 27 42 32 41 41
Selling, General & Admin Expense		 2.59 3.34 3.91 4.76 6.76 7.46 7.22 7.70 8.13
Research & Development Expense		 6.90 12 16 16 20 34 25 33 33
Total Other Income / (Expense), net		 -13 2.87 2.70 3.15 5.87 5.01 4.68 4.39 3.79
Interest & Investment Income		 0.01 2.87 2.70 3.15 5.87 5.01 4.68 4.39 3.79
Income Tax Expense		 0.00 0.00 0.00 0.00 0.19 0.07 0.05 0.04 0.05
Basic Earnings per Share		 ($38.23) ($18.94) ($19.01) ($1.60) $35.50 ($0.68) ($0.50) ($0.67) ($0.67)
Weighted Average Basic Shares Outstanding		 597.59K 660.29K 896.74K 10.90M 16.81M 54.46M 54.54M 54.56M 54.68M
Diluted Earnings per Share		 ($38.23) ($18.94) ($19.01) ($1.60) $35.50 ($0.68) ($0.50) ($0.67) ($0.67)
Weighted Average Diluted Shares Outstanding		 597.59K 660.29K 896.74K 10.90M 16.81M 54.46M 54.54M 54.56M 54.68M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 54.42M 54.52M 54.54M 54.56M 54.78M 65.47M

Annual Cash Flow Statements for Bicara Therapeutics

This table details how cash moves in and out of Bicara Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 226 259 -393
Net Cash From Operating Activities		 -46 -75 -107
Net Cash From Continuing Operating Activities		 -46 -75 -107
Net Income / (Loss) Continuing Operations		 -52 -68 -138
Consolidated Net Income / (Loss)		 -52 -68 -138
Depreciation Expense		 0.02 0.06 0.11
Amortization Expense		 - 0.00 0.30
Non-Cash Adjustments To Reconcile Net Income		 16 7.40 15
Changes in Operating Assets and Liabilities, net		 -9.58 -14 16
Net Cash From Investing Activities		 -0.59 -0.01 -318
Net Cash From Continuing Investing Activities		 -0.59 -0.01 -318
Purchase of Property, Plant & Equipment		 -0.59 -0.07 -0.28
Purchase of Investments		 - 0.00 -318
Sale of Property, Plant & Equipment		 0.00 0.06 0.00
Net Cash From Financing Activities		 272 334 32
Net Cash From Continuing Financing Activities		 272 334 32
Issuance of Common Equity		 0.00 332 29
Other Financing Activities, net		 0.15 1.60 2.76

Quarterly Cash Flow Statements for Bicara Therapeutics

This table details how cash moves in and out of Bicara Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 186 -14 -12 317 -31 -28 -25 -265 -75
Net Cash From Operating Activities		 -8.04 -15 -13 -17 -30 -28 -26 -29 -24
Net Cash From Continuing Operating Activities		 -8.04 -15 -13 -17 -30 -28 -26 -29 -24
Net Income / (Loss) Continuing Operations		 -12 -13 -17 -17 -21 -37 -27 -36 -37
Consolidated Net Income / (Loss)		 -12 -13 -17 -17 -21 -37 -27 -36 -37
Depreciation Expense		 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.02 0.04
Amortization Expense		 - 0.07 0.07 0.07 - 0.14 0.21 -0.32 0.27
Non-Cash Adjustments To Reconcile Net Income		 1.41 1.15 0.90 1.96 3.20 3.45 3.17 4.54 3.81
Changes in Operating Assets and Liabilities, net		 2.98 -3.30 3.16 -1.79 -12 5.13 -1.61 2.84 9.37
Net Cash From Investing Activities		 -0.44 0.06 -0.02 -0.01 -0.04 0.00 - -236 -82
Net Cash From Continuing Investing Activities		 -0.44 0.06 -0.02 -0.01 -0.04 0.00 - -236 -82
Purchase of Property, Plant & Equipment		 -0.44 -0.00 -0.02 -0.01 -0.04 0.00 - -0.04 -0.24
Purchase of Investments		 - - - - - - - - -82
Net Cash From Financing Activities		 195 0.14 0.73 334 -0.98 0.46 0.14 0.44 31
Net Cash From Continuing Financing Activities		 195 0.14 0.73 334 -0.98 0.46 0.14 0.44 31
Issuance of Common Equity		 - - - - -1.05 - - - 29
Other Financing Activities, net		 - 0.14 1.33 0.06 0.08 0.46 0.14 0.44 1.73

Annual Balance Sheets for Bicara Therapeutics

This table presents Bicara Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets		 234 510 431
Total Current Assets		 231 503 422
Cash & Equivalents		 230 490 97
Short-Term Investments		 - 0.00 318
Prepaid Expenses		 0.63 13 7.25
Plant, Property, & Equipment, net		 0.20 0.16 0.33
Total Noncurrent Assets		 2.71 7.31 8.61
Other Noncurrent Operating Assets		 2.71 7.31 8.61
Total Liabilities & Shareholders' Equity		 234 510 431
Total Liabilities		 15 18 30
Total Current Liabilities		 15 18 29
Accounts Payable		 3.19 4.51 7.79
Accrued Expenses		 12 13 20
Other Current Liabilities		 0.29 0.61 1.12
Total Noncurrent Liabilities		 0.39 0.13 0.59
Other Noncurrent Operating Liabilities		 0.39 0.13 0.59
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -149 492 401
Total Preferred & Common Equity		 -149 492 401
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 -149 492 401
Common Stock		 4.25 713 760
Retained Earnings		 -153 -221 -359
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 0.24

Quarterly Balance Sheets for Bicara Therapeutics

This table presents Bicara Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 524 478 454 425
Total Current Assets		 522 471 444 297
Cash & Equivalents		 521 462 437 172
Short-Term Investments		 - - - 118
Prepaid Expenses		 0.76 8.69 7.79 7.21
Plant, Property, & Equipment, net		 0.13 0.14 0.12 0.14
Total Noncurrent Assets		 2.53 7.19 9.08 127
Long-Term Investments		 - - - 117
Other Noncurrent Operating Assets		 2.53 7.19 9.08 9.76
Total Liabilities & Shareholders' Equity		 524 478 454 425
Total Liabilities		 15 19 18 22
Total Current Liabilities		 14 19 17 21
Accounts Payable		 1.96 2.74 2.91 3.66
Accrued Expenses		 12 16 13 16
Other Current Liabilities		 0.31 0.59 1.07 1.10
Total Noncurrent Liabilities		 0.14 0.00 1.16 0.88
Other Noncurrent Operating Liabilities		 0.14 0.00 1.16 0.88
Commitments & Contingencies		 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 510 459 435 403
Total Preferred & Common Equity		 510 459 435 403
Preferred Stock		 0.00 0.00 0.00 0.00
Total Common Equity		 510 459 435 403
Common Stock		 710 717 720 724
Retained Earnings		 -200 -258 -285 -322
Accumulated Other Comprehensive Income / (Loss)		 - - - -0.14

Annual Metrics And Ratios for Bicara Therapeutics

This table displays calculated financial ratios and metrics derived from Bicara Therapeutics' official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - 54,781,950.00
DEI Adjusted Shares Outstanding		 - - 54,781,950.00
DEI Earnings Per Adjusted Shares Outstanding		 - - -2.52
Growth Metrics		 - - -
Profitability Metrics		 - - -
Net Operating Profit after Tax (NOPAT)		 -28 -58 -109
Return On Investment Capital (ROIC_SIMPLE)		 18.77% -11.73% -27.13%
Earnings before Interest and Taxes (EBIT)		 -53 -82 -156
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -53 -82 -155
Valuation Ratios		 - - -
Leverage & Solvency		 - - -
Liquidity Ratios		 - - -
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -72 -93
Efficiency Ratios		 - - -
Capital & Investment Metrics		 - - -
Invested Capital		 -12 2.16 -13
Increase / (Decrease) in Invested Capital		 0.00 14 -16
Book Value per Share		 ($256.45) $9.04 $7.33
Tangible Book Value per Share		 ($256.45) $9.04 $7.33
Total Capital		 219 492 401
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -230 -490 -415
Capital Expenditures (CapEx)		 0.59 0.01 0.28
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -14 -5.17 -22
Debt-free Net Working Capital (DFNWC)		 216 485 393
Net Working Capital (NWC)		 216 485 393
Net Nonoperating Expense (NNE)		 24 10 29
Net Nonoperating Obligations (NNO)		 -230 -490 -415
Total Depreciation and Amortization (D&A)		 0.02 0.06 0.41
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 ($4.05) ($2.52)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 16.81M 54.68M
Adjusted Diluted Earnings per Share		 $0.00 ($4.05) ($2.52)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 16.81M 54.68M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 54.52M 65.47M
Normalized Net Operating Profit after Tax (NOPAT)		 -28 -58 -109
Debt Service Ratios		 - - -
Payout Ratios		 - - -

Quarterly Metrics And Ratios for Bicara Therapeutics

This table displays calculated financial ratios and metrics derived from Bicara Therapeutics' official financial filings.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
DEI Shares Outstanding		 - - - - 54,415,619.00 - - - 54,781,950.00
DEI Adjusted Shares Outstanding		 - - - - 54,415,619.00 - - - 54,781,950.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - -0.39 - - - -0.68
Growth Metrics		 - - - - - - - - -
Profitability Metrics		 - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -6.67 -11 -14 -14 -19 -29 -22 -28 -29
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -3.79% -6.37% -5.15% -7.07% -7.17%
Earnings before Interest and Taxes (EBIT)		 -23 -15 -20 -21 -27 -42 -32 -41 -41
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -23 -15 -20 -21 -27 -42 -32 -41 -41
Valuation Ratios		 - - - - - - - - -
Leverage & Solvency		 - - - - - - - - -
Liquidity Ratios		 - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 -3.24 0.00 -26 -21 -35 -13
Efficiency Ratios		 - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 0.00 0.00 0.00 -11 2.16 -3.11 -1.41 -4.80 -13
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 -11 0.00 -3.11 -1.41 6.40 -16
Book Value per Share		 $0.00 $0.00 $0.00 $46.74 $9.04 $8.42 $7.98 $7.38 $7.33
Tangible Book Value per Share		 $0.00 $0.00 $0.00 $46.74 $9.04 $8.42 $7.98 $7.38 $7.33
Total Capital		 0.00 0.00 0.00 510 492 459 435 403 401
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 0.00 0.00 -521 -490 -462 -437 -408 -415
Capital Expenditures (CapEx)		 0.00 -0.06 0.02 0.00 0.04 0.00 0.00 0.04 0.24
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 -14 -5.17 -10 -9.44 -14 -22
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 507 485 452 427 276 393
Net Working Capital (NWC)		 0.00 0.00 0.00 507 485 452 427 276 393
Net Nonoperating Expense (NNE)		 16 1.75 3.22 3.04 2.31 7.59 4.98 7.86 8.60
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 -521 -490 -462 -437 -408 -415
Total Depreciation and Amortization (D&A)		 0.00 0.08 0.08 0.00 -0.18 0.16 0.23 -0.29 0.31
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($1.60) $35.50 ($0.68) ($0.50) ($0.67) ($0.67)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 10.90M 16.81M 54.46M 54.54M 54.56M 54.68M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($1.60) $35.50 ($0.68) ($0.50) ($0.67) ($0.67)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 10.90M 16.81M 54.46M 54.54M 54.56M 54.68M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 54.42M 54.52M 54.54M 54.56M 54.78M 65.47M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.67 -11 -14 -14 -19 -29 -22 -28 -29
Debt Service Ratios		 - - - - - - - - -
Payout Ratios		 - - - - - - - - -

Financials Breakdown Chart

Key Financial Trends

Here are key trends from Bicara Therapeutics (BCAX) across quarterly reports over the last four years, focusing on cash flow, profitability, and the balance sheet. Items are shown with positives first, then neutral, then negatives.

  • Q4 2025: Issuance of Common Equity added about $29.5 million in cash, and net financing cash flow was roughly $31.2 million, boosting near-term liquidity.
  • Historical funding activity has provided runway to support R&D (for example, Q4 2023 saw a significant cash inflow from issuance of Preferred Equity of about $194.7 million).
  • Balance sheet shows a strong equity cushion with relatively low liabilities: in 2025 Q3, Total Liabilities were about $21.9 million versus Total Assets around $424.7 million, indicating modest leverage.
  • A sizable cash cushion has existed in prior periods (e.g., Cash & Equivalents around $520.8 million in 2024 Q3 and about $462.1 million in 2025 Q1), providing liquidity headroom for clinical development.
  • Total revenue has been minimal or zero in most quarters, consistent with Bicara’s ongoing pre-revenue development stage.
  • Weighted-average shares outstanding are in the mid-50 million range (roughly 54.5–54.6 million in 2025), indicating some dilution risk from equity financing while keeping per-share losses in check with higher share counts.
  • R&D and SG&A expenses dominate operating costs, signaling continued heavy investment in clinical programs rather than near-term profitability.
  • Net cash from continuing operating activities is negative in every reported 2025 quarter, reflecting ongoing cash burn from operations.
  • Investing activities show substantial cash outflows in mid-2025 (approximately $236.1 million in Q3 2025 and about $82.1 million in Q2 2025), indicating significant capital deployment alongside ongoing development efforts.
  • Net income attributable to common shareholders was negative in 2025 Q4, around $-37.386 million, consistent with ongoing losses and no material revenue.
05/07/26 06:54 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Bicara Therapeutics' Financials

When does Bicara Therapeutics' financial year end?

According to the most recent income statement we have on file, Bicara Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has Bicara Therapeutics' net income changed over the last 2 years?

Bicara Therapeutics' net income appears to be on an upward trend, with a most recent value of -$137.95 million in 2025, rising from -$51.99 million in 2023. The previous period was -$68.00 million in 2024. See where experts think Bicara Therapeutics is headed by visiting Bicara Therapeutics' forecast page.

What is Bicara Therapeutics' operating income?
Bicara Therapeutics' total operating income in 2025 was -$155.60 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $155.60 million
How has Bicara Therapeutics' revenue changed over the last 2 years?

Over the last 2 years, Bicara Therapeutics' total revenue changed from $0.00 in 2023 to $0.00 in 2025, a change of 0.0%.

How much debt does Bicara Therapeutics have?

Bicara Therapeutics' total liabilities were at $29.54 million at the end of 2025, a 63.0% increase from 2024, and a 90.9% increase since 2023.

How much cash does Bicara Therapeutics have?

In the past 2 years, Bicara Therapeutics' cash and equivalents has ranged from $96.69 million in 2025 to $489.71 million in 2024, and is currently $96.69 million as of their latest financial filing in 2025.

How has Bicara Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Bicara Therapeutics' book value per share changed from -256.45 in 2023 to 7.33 in 2025, a change of -102.9%.


Related Companies

Financial statements for NASDAQ:BCAX last updated on 4/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel